Humanigen Stock Price

0.2501 (1.19%)
Upgrade to Real-Time
Afterhours (Closed)


52 Week Range


Best deals to access real time data!
Big Cap Pro
Monthly Subscription
for only
Small Cap Basic
Monthly Subscription
for only
Real-Time Alerts for Volume Breakouts, Highs and Lows for NYSE, NASDAQ, Amex, OTC Markets and OTCBB
Monthly Subscription
for only
VAT not included
Company Name Stock Ticker Symbol Market Type
Humanigen Inc HGEN NASDAQ Common Stock
  Price Change Change Percent Stock Price Last Traded
0.2501 1.19% 21.3201 20:00:00
Open Price Low Price High Price Close Price Prev Close
21.54 20.90 22.37 21.11 21.07
Bid Price Ask Price Spread News
21.32 21.51 0.19 - -
Trades Volume VWAP Dollar Volume Avg Volume 52 Week Range
9,391 920,824 $ 21.53 $ 19,829,848 1,349,160 7.75 - 29.20
Last Trade Time Type Quantity Stock Price Currency
19:59:52 formt 351 $ 21.3201 USD

Humanigen Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
$ 1.26B 59.08M 37.79M $ - $ - -2.25 -6.40
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- $ - - 404.42k 1.20%

more financials information »

Humanigen News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....

No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts

Historical HGEN Price Data

Period Open High Low VWAP Avg. Daily Vol Change %
1 Week18.0622.3717.8820.571,116,7163.2618.05%
1 Month18.0423.5317.2519.841,318,1873.2818.18%
3 Months16.3329.2012.317119.763,168,1894.9930.56%
6 Months9.6029.209.2419.202,013,14411.72122.08%
1 Year10.8529.207.7518.111,600,61910.4796.5%
3 Years10.8529.207.7518.111,600,61910.4796.5%
5 Years10.8529.207.7518.111,600,61910.4796.5%

Humanigen Description

Humanigen Inc is a biopharmaceutical company engaged in the development of proprietary monoclonal antibodies for various oncology indications and to enhance T-cell therapies, making these treatments safer and cost-effective. It focuses on preventing the serious and potentially life-threatening side-effects associated with chimeric antigen receptor T-cell (CAR-T) therapy. Its pipeline includes programs such as Lenzilumab, Ifabotuzumab, and HGen005.

Your Recent History
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.